THTafhima Haider

Tafhima Haider

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tafhima Haider has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Beatrice Amadi

    Tropical Gastroenterology and Nutrition group (TROPGAN), University of Zambia School of Medicine, Lusaka, Zambia

    3 shared publications
  • Ellen Besa

    Tropical Gastroenterology and Nutrition group (TROPGAN), University of Zambia School of Medicine, Lusaka, Zambia

    3 shared publications
  • Mutsa Bwakura-Dangarembizi

    Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

    3 shared publications
  • Paul Kelly

    Tropical Gastroenterology and Nutrition Group, University of Zambia School of Medicine, Lusaka, Zambia

    3 shared publications
  • Tracy Naomi Phiri

    Tropical Gastroenterology & Nutrition group, University of Zambia School of Medicine, Lusaka, Lusaka Province

    3 shared publications
  • Alex J. Thompson

    Imperial College London Faculty of Medicine, London, England, W12 0NN

    2 shared publications

Latest Publications

  • Open Access

    Antenatal inflammation drives postpartum cardiac dysfunction in hypertensive disorders of pregnancy

    by Serena Bert, Alice P. Christensen, Mirko Bulletti, Eleanor J. Ward, Una Rose Wilcox, Joshua P. Dignam, Tafhima Haider, En Ping Yap, Kerri M. Malone, Robert T. Maughan, et al.

    Hypertensive disorders of pregnancy (HDPs), including preeclampsia and gestational hypertension, are strongly associated with maternal cardiac dysfunction during and after pregnancy. We hypothesized that maternal inflammation drives persistent postpartum cardiac maladaptation after HDPs. We conducted a prospective longitudinal study assessing cardiac function and circulating inflammatory profiles during pregnancy and 3–6 months postpartum, complemented by a preclinical mechanistic mouse model recapitulating key antenatal and postpartum immune and cardiac features of HDPs. Here we show that distinct antenatal inflammatory signatures, including elevated chemokines, correlated with adverse left ventricular structure and function 3–6 months postpartum, despite resolution of systemic inflammation. Mechanistically, our preclinical HDP mouse model demonstrates that reduced antenatal progesterone, also observed in patients with HDPs, drives inflammation and postpartum cardiac dysfunction. Antenatal (embryonic day 14.5), but not postpartum (postpartum day 28), progesterone treatment prevented postpartum cardiac dysfunction, identifying both a potential mechanistic and therapeutic strategy to reduce long-term maternal cardiovascular morbidity.

  • Open Access

    Restoration of anti-bacterial innate immune cell function lags behind nutritional recovery among children convalescing from complicated severe acute malnutrition

    by Sandra Rukobo, Kuda Mutasa, Tracy N. Phiri, Margaret Govha, Patience Mushayanembwa, Simutanyi Mwakamui, Tafhima Haider, Ellen Besa, Kanekwa Zyambo, Cherlynn Dumbura, et al.

    Children recovering from complicated severe acute malnutrition (SAM) have a high risk of infectious mortality and morbidity, which could reflect impaired anti-microbial defence. We used blood samples from a cross-sectional cohort of children under 5 years’ old admitted to hospital with SAM in Zambia and Zimbabwe (cases, n = 125) and adequately nourished non-hospitalised children from the same communities (controls, n = 73) to characterise anti-bacterial innate immune cell function. We did not find evidence that inpatient immune function differed between cases who experienced subsequent adverse clinical outcomes (death, readmission, SAM at 48 weeks) versus those who did not. However, pro-inflammatory cytokine (IL-6, IL-8 and TNF) responses to E. coli lipopolysaccharide and heat-killed Salmonella typhimurium were positively associated with subsequent gains in mid-upper arm circumference, an indicator of nutritional recovery. We then characterised how innate immune cell function changed during post-discharge rehabilitation in a longitudinal sub-cohort of cases who provided repeat blood samples at discharge, 12, 24 and/or 48 weeks post-discharge ( n = 83). Relative to inpatient immune function, bacterial binding capacity declined whilst anti-bacterial pro-inflammatory cytokine secretion increased in the cases over the post-discharge follow-up period with both normalising towards control ranges. These changes were also evident in cases who had recovered to a healthy nutritional status (weight-for-height Z score ≥ −2). Collectively, our data suggest that restoration of anti-bacterial innate immune cell function following complicated SAM lags behind nutritional recovery. Thus, children who are no longer wasted may continue to have deficient anti-bacterial innate immunity months after hospital admission for SAM.

  • Open Access

    Novel gastrointestinal tools (GI Tools) for evaluating gut functional capacity in adults with environmental enteropathy in Zambia and Zimbabwe: A cross-sectional study protocol

    by Tracy N. Phiri, James W. Weatherill, Elena Monford-Sanchez, Jose-Ivan Serrano-Contreras, Callum Melvin, Mirriam Kunaka, Ian Chisenga, Perpetual Ngalande, Monica N. Mweetwa, Ellen Besa, et al.

    Background Environmental enteropathy (EE) is a highly prevalent subclinical inflammatory intestinal disorder associated with growth failure, impaired neurocognitive development, poor response to oral vaccines, and micronutrient deficiencies. However, EE research and clinical trials are hampered by the lack of non-invasive tools for measuring intestinal function in detail. This study aims to develop new tools for the measurement of multiple domains of gut functional capacity. Methods The GI TOOLS project is a cross-sectional study that will recruit adults aged 18-65 years with EE in Lusaka, Zambia. Each participant will undergo assessment of gut functional capacity using novel near-point-of-care tools and provide multiple samples for detailed laboratory analyses. Participants will also undergo endoscopy for collection of duodenal biopsies. Novel techniques include stable isotopes approaches to measuring digestion, absorption, and bidirectional transmucosal amino acid flux, a non-invasive fluorescence tool for real-time evaluation of gut permeability, and assessment of reverse permeation of intravenous antibiotics to be carried out separately in Zimbabwe. Stool and duodenal microbiome sequencing using MinION sequencing, metabolome analysis applied to plasma and intestinal fluids, blood immune cell phenotyping, in vitro epithelial barrier models, and duodenal immunohistochemistry will also be used to explore EE in depth. These will all be integrated with gold standard histology and mucosal morphometry, alongside lactulose permeation data, and stool and plasma biomarker analysis. The protocol has been approved by ethics committees and regulators in Zambia, Zimbabwe, and the UK. Participants will give informed consent before they can participate Anticipated outcomes Based on this extensive phenotyping, tests will be developed which can be simplified and refined for use in adults and children with EE, and for clinical trials. Findings from this project will be disseminated through in-person meetings with caregivers and regulatory bodies, presentations at conferences and in peer-reviewed journals.


  • Open Access

    Novel gastrointestinal tools (GI Tools) for evaluating gut functional capacity in adults with environmental enteropathy in Zambia and Zimbabwe: A cross-sectional study protocol

    by Tracy N. Phiri, James W. Weatherill, Elena Monford-Sanchez, Jose-Ivan Serrano-Contreras, Callum Melvin, Mirriam Kunaka, Ian Chisenga, Perpetual Ngalande, Monica N. Mweetwa, Ellen Besa, et al.

    Background Environmental enteropathy (EE) is a highly prevalent subclinical inflammatory intestinal disorder associated with growth failure, impaired neurocognitive development, poor response to oral vaccines, and micronutrient deficiencies. However, EE research and clinical trials are hampered by the lack of non-invasive tools for measuring intestinal function in detail. This study aims to develop new tools for the measurement of multiple domains of gut functional capacity. Methods The GI TOOLS project is a cross-sectional study that will recruit adults aged 18-65 years with EE in Lusaka, Zambia. Each participant will undergo assessment of gut functional capacity using novel near-point-of-care tools and provide multiple samples for detailed laboratory analyses. Participants will also undergo endoscopy for collection of duodenal biopsies. Novel techniques include stable isotopes approaches to measuring digestion, absorption, and bidirectional transmucosal amino acid flux, a non-invasive fluorescence tool for real-time evaluation of gut permeability, and assessment of reverse permeation of intravenous antibiotics to be carried out separately in Zimbabwe. Stool and duodenal microbiome sequencing using MinION sequencing, metabolome analysis applied to plasma and intestinal fluids, blood immune cell phenotyping, in vitro epithelial barrier models, and duodenal immunohistochemistry will also be used to explore EE in depth. These will all be integrated with gold standard histology and mucosal morphometry, alongside lactulose permeation data, and stool and plasma biomarker analysis. The protocol has been approved by ethics committees and regulators in Zambia, Zimbabwe, and the UK. Participants will give informed consent before they can participate Anticipated outcomes Based on this extensive phenotyping, tests will be developed which can be simplified and refined for use in adults and children with EE, and for clinical trials. Findings from this project will be disseminated through in-person meetings with caregivers and regulatory bodies, presentations at conferences and in peer-reviewed journals.


  • Open Access

    Severe acute malnutrition promotes bacterial binding over proinflammatory cytokine secretion by circulating innate immune cells

    by Tracy N. Phiri, Kuda Mutasa, Sandra Rukobo, Margaret Govha, Patience Mushayanembwa, Simutanyi Mwakamui, Tafhima Haider, Kanekwa Zyambo, Cherlynn Dumbura, Joice Tome, et al.

    Children with severe acute malnutrition (SAM) have high infectious mortality and morbidity, implicating defects in their immune defenses. We hypothesized that circulating innate immune cells from children (0 to 59 months) hospitalized with SAM in Zambia and Zimbabwe ( n = 141) have distinct capacity to respond to bacteria relative to adequately nourished healthy controls ( n = 92). SAM inpatients had higher neutrophil and monocyte Escherichia coli binding capacity but lower monocyte activation and proinflammatory mediator secretion in response to lipopolysaccharide or heat-killed Salmonella typhimurium than controls. Among SAM cases, wasting severity was negatively associated with cytokine secretion, children with HIV had lower monocyte activation, and the youngest children released the least myeloperoxidase upon stimulation. Inpatient bacterial binding capacity and monocyte activation were associated with higher odds of persistent SAM at discharge, a risk factor for subsequent mortality. Thus, SAM shifts innate immune cell function, favoring bacterial containment over proinflammatory activation, which may contribute to health deficits after discharge.


  • Open Access

    SARS-CoV-2 evolution influences GBP and IFITM sensitivity

    by Dejan Mesner, Ann-Kathrin Reuschl, Matthew V. X. Whelan, Taylor Bronzovich, Tafhima Haider, Lucy G. Thorne, Roberta Ragazzini, Paola Bonfanti, Greg J. Towers, Clare Jolly

    SARS-CoV-2 spike requires proteolytic processing for viral entry. A polybasic furin-cleavage site (FCS) in spike, and evolution toward an optimized FCS by dominant variants of concern (VOCs), are linked to enhanced infectivity and transmission. Here we show interferon-inducible restriction factors Guanylate-binding proteins (GBP) 2 and 5 interfere with furin-mediated spike cleavage and inhibit the infectivity of early-lineage isolates Wuhan-Hu-1 and VIC. By contrast, VOCs Alpha and Delta escape restriction by GBP2/5 that we map to the spike substitution D614G present in these VOCs. Despite inhibition of spike cleavage, these viruses remained sensitive to plasma membrane IFITM1, but not endosomal IFITM2 and 3, consistent with a preference for TMPRSS2-dependent plasma membrane entry. Strikingly, we find that Omicron is unique among VOCs, being sensitive to restriction factors GBP2/5, and also IFITM1, 2, and 3. Using chimeric spike mutants, we map the Omicron phenotype and show that the S1 domain determines Omicron’s sensitivity to GBP2/5, whereas the S2’ domain determines its sensitivity to endosomal IFITM2/3 and preferential use of TMPRSS2-independent entry. We propose that evolution of SARS-CoV-2 for the D614G substitution has allowed for escape from GBP restriction factors, but the selective pressures on Omicron for spike changes that mediate antibody escape, and altered tropism, have come at the expense of increased sensitivity to innate immune restriction factors that target virus entry.


  • Open Access

    HIV envelope tail truncation confers resistance to SERINC5 restriction

    by Tafhima Haider, Xenia Snetkov, Clare Jolly

    Significance: SERINCs and IFITMs are potent lentiviral restriction factors that inhibit infection by blocking viral entry into cells. Specifically, SERINCs inhibit viral fusion by targeting the envelope glycoprotein (Env) by a mechanism that remains incompletely understood. Here, we report that truncation of the Env cytoplasmic tail (CT) of HIV-1 and HIV-2 confers complete resistance to SERINC and IFITM restriction. Notably, while the EnvCT of HIV-1 is necessary for viral replication in T cells, HIV-2 does not require the EnvCT. Our data suggest a mechanism by which human lentiviruses can evade restriction that is mediated by the EnvCT but reveal key differences in the likely fitness cost imposed by this on pandemic HIV-1 and nonpandemic HIV-2.